MentionFox
Home › funding signals › Theriva Biologics, Inc.
Form D · on the record

Theriva Biologics — $13.11M Form D filing, October 2025

Theriva Biologics, Inc. filed a Form D with the Securities and Exchange Commission on 2025-10-24.

Theriva Biologics, Inc. filed a Form D notice of an exempt securities offering with the SEC on October 24, 2025. Theriva Biologics, Inc. trades on NYSE as TOVX; it was formerly Synthetic Biologics, Inc. The filing reports $13.11M sold. Its industry group is Biotechnology. It names Steven Shallcross (Executive Officer, Director), Jeffrey Kraws (Director), John Monahan (Director) (SEC Form D, October 24, 2025).

In its own words: “DELIVERING A NEW CLASS OF ONCOLYTIC VIRUS THERAPEUTICS ABOUT THERIVA™ Theriva is a clinical-stage immuno-oncology company developing oncolytic viruses inten ...” (therivabio.com, checked November 1, 2026)

4 more Biotechnology raises in Maryland within 90 days ↓

Is this your company?

Key facts

Run the free check on Theriva Biologics, Inc. →

Sell to companies like Theriva Biologics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Theriva Biologics, Inc.

New Form D on file · 2025-10-24 · the record

$13.11M
raise on the record
D
filing
10
investors in
MARYLAND
based
Open the record →

What the record says

FilingForm D
Filed2025-10-24
Industry groupBiotechnology
Entity typeCorporation
Incorporated inNEVADA
BasedROCKVILLE, MARYLAND
CIK894158
Accession0001104659-25-101914

Pitching, partnering or investing alongside them? See who really runs and owns Theriva Biologics, Inc.

Watch Theriva Biologics, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on the people and the money behind Theriva Biologics, Inc., from the filings we hold.

More raises like this

Biotechnology raises by companies based in Maryland, filed within 90 days of this one, largest first.

What do you want to do with Theriva Biologics, Inc.?

Get the full cited report on Theriva Biologics, Inc.

What the filing shows about Theriva Biologics, Inc.

  • 10 investors had already put money in when it filed.
  • The filing names 4 people as officers, directors or promoters.

Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on Theriva Biologics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

See a sample report

Who the filing names, and in what role

The filing gives Theriva Biologics, Inc.'s address as 9605 Medical Center Drive, Suite 270, Rockville, MD 20850.

What the filing says

  • Offered: $13,109,494. Sold: $13,109,494. Left to sell: nothing, all of it is sold. (filing)
  • Investors: 10 had already invested. (filing)
  • Date of first sale: October 17, 2025. (filing)
  • Types of securities: Options, warrants or other rights to acquire another security; Securities to be acquired on exercise of an option, warrant or other right. (filing)
  • Item 16: the filing reports that none of the proceeds goes to executive officers, directors or promoters. It adds: “While no offering proceeds are set aside for payments to the named officers or directors, it is possible that some proceeds to be used as working capital will be used indirectly for paying salaries to employees including executive officers” (filing)
  • On the amounts offered and sold: the filing adds “Includes $4,369,831.20 in proceeds from exercise of existing registered warrants pursuant to Warrant Inducement Letter Agreement and $8,739,663 in total gross proceeds to be received from cash exercise of all new warrants issued in private placement.” (filing)
  • On sales commissions and finders' fees: the filing adds “A.G.P/Alliance Global Partners LP was paid by the Issuer a cash fee equal to 7.0% of the aggregate gross proceeds received upon exercise of the existing registered warrants and reimbursement of certain expenses.” (filing)

This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.

Order the Full Report on Theriva Biologics, Inc. See pricing

Is Theriva Biologics, Inc. a real, registered company?

Theriva Biologics, Inc. is a registered filer with the SEC (CIK 894158) and has filed since 2025-10-24. 1 filing is on record, the latest on 2025-10-24.

A filing shows the company exists and what it reports about itself. It is not an audit or a rating.

Who runs Theriva Biologics, Inc.?

Theriva Biologics, Inc.'s Form D of 2025-10-24 names Steven Shallcross, Jeffrey Kraws, John Monahan and 1 more as its officers, directors or promoters.

How much has Theriva Biologics, Inc. raised?

Its new offerings report $13.11M sold across 1 offering, as its own filings state.

Biotechnology · by week

Trailing twelve months. 766 filings in Biotechnology, totalled by week.

Want the whole picture on Theriva Biologics, Inc.?

What the filing shows about Theriva Biologics, Inc.

  • 10 investors had already put money in when it filed.
  • The filing names 4 people as officers, directors or promoters.

Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on Theriva Biologics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Theriva Biologics, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    2 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

The full profile

Checking your access…

Is this you?

If you're behind Theriva Biologics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.

Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-10-30 (therivabio.com).

RSS

Tools for this story

Each opens in a new tab, filled in for Theriva Biologics, Inc.. With no account yet, you sign up free and land on the result.

More on Theriva Biologics, Inc.

On these lists: Biotech raises in Washington, DC

Share this page

Is this your company?

Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.

Theriva Biologics, Inc.: Raised $13.11M, Form D filed 2025-10-24
Share on LinkedIn Share on X Download image

Cite this page

Permanent URL: https://mentionfox.com/funding/theriva-biologics-inc-form-d-25000001
Last updated 2026-10-30
Primary record: SEC filing 1 · SEC filing 2
Theriva Biologics raised $13.11M — SEC Form D filing, October 2025. MentionFox, 2026-10-30. https://mentionfox.com/funding/theriva-biologics-inc-form-d-25000001